Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by Polar Asset Management Partners Inc.

Polar Asset Management Partners Inc. raised its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 1,144.1% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 282,400 shares of the company’s stock after purchasing an additional 259,700 shares during the period. Polar Asset Management Partners Inc.’s holdings in Intellia Therapeutics were worth $3,293,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. ARK Investment Management LLC grew its holdings in Intellia Therapeutics by 2.3% in the fourth quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company’s stock valued at $146,174,000 after purchasing an additional 280,946 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Intellia Therapeutics by 5.8% during the fourth quarter. Vanguard Group Inc. now owns 10,190,053 shares of the company’s stock valued at $118,816,000 after acquiring an additional 562,249 shares during the last quarter. Regeneron Pharmaceuticals Inc. acquired a new stake in shares of Intellia Therapeutics during the fourth quarter valued at $43,177,000. Geode Capital Management LLC boosted its stake in shares of Intellia Therapeutics by 2.0% during the fourth quarter. Geode Capital Management LLC now owns 2,389,240 shares of the company’s stock valued at $27,865,000 after acquiring an additional 45,930 shares during the last quarter. Finally, Two Sigma Advisers LP boosted its stake in shares of Intellia Therapeutics by 94.5% during the fourth quarter. Two Sigma Advisers LP now owns 1,998,317 shares of the company’s stock valued at $23,300,000 after acquiring an additional 970,700 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $13.00 price objective (down previously from $45.00) on shares of Intellia Therapeutics in a research note on Friday, February 28th. Wall Street Zen raised Intellia Therapeutics to a “sell” rating in a research note on Monday, March 3rd. Guggenheim decreased their price objective on Intellia Therapeutics from $55.00 to $45.00 and set a “buy” rating on the stock in a research note on Monday, May 12th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Intellia Therapeutics in a research note on Tuesday, May 20th. Finally, Citigroup decreased their price objective on Intellia Therapeutics from $14.00 to $10.00 and set a “neutral” rating on the stock in a research note on Friday, May 9th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $36.90.

Intellia Therapeutics Price Performance

Intellia Therapeutics stock opened at $9.16 on Monday. The stock’s 50-day moving average is $7.98 and its 200-day moving average is $10.51. The company has a market cap of $948.82 million, a price-to-earnings ratio of -1.68 and a beta of 2.33. Intellia Therapeutics, Inc. has a 12 month low of $5.90 and a 12 month high of $28.18.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.16. The firm had revenue of $16.63 million during the quarter, compared to analysts’ expectations of $11.39 million. The business’s revenue for the quarter was down 42.6% compared to the same quarter last year. During the same quarter last year, the business earned ($1.12) earnings per share. Research analysts anticipate that Intellia Therapeutics, Inc. will post -5.07 EPS for the current year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.